Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 353

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 353
---
 an attestation report of our registered public accounting firm regarding internal control over financial
reporting due to an exemption provided to issuers that are not “large accelerated filers” nor “accelerated filers”
under applicable SEC rules.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

Item
9B. Other Information.

During
the three months ended December 31, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of
the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
as each term is defined in Item 408(a) of Regulation S-K.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not
applicable.

PART
III

Item
10. Directors and Executive Officers.

The
following table sets forth information relating to our executive officers and directors as of March 12, 2025.

    Name
     
    Age
     
    Position
  
    Executive
    Officers

    Jeffrey
    A. Meckler
     
    58
     
    Chief
    Executive Officer and Director
  
    Michael
    J. Newman, Ph.D.
     
    69
     
    Chief
    Scientific Officer and Director
  
    Nir
    Sassi
     
    49
     
    Chief
    Financial Officer
  
    Walt
    A. Linscott, Esq.
     
    65
     
    Chief
    Operating Officer
  
    Roger
    J. Waltzman
     
    58
     
    Chief
    Medical Officer

    Non-Executive
    Directors

    Dr.
    Roger J. Pomerantz
     
    68
     
    Chairman
    of the Board of Directors
  
    Hila
    Karah
     
    56
     
    Director
  
    Anthony
    J. Maddaluna
     
    72
     
    Director
  
    William
    B. Hayes